Overview

Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency

Status:
Not yet recruiting

Trial end date:
2023-12-01

Target enrollment:
0

Participant gender:
All

Summary

This is a 3-year prospective study too identify the role of exocrine pancreatic insufficiency in patients with abdominal pain who are undergoing upper endoscopy. An endoscopic pancreatic function test (ePFT) with secretin will be performed in children undergoing routine investigative EGD. The goal of this study is to identify the role of exocrine pancreatic insufficiency in patients with abdominal pain who are undergoing upper endoscopy, who otherwise would be labelled as recurrent abdominal pain (RAP).

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Orlando Health, Inc.

Collaborator:

ChiRhoClin, Inc.

Treatments:

Secretin

Criteria

Inclusion Criteria:

- For Group 1- Patients undergoing EGD with ePFT for symptoms of suspected or known
pancreatic insufficiency

- For Group 2- Patients undergoing diagnostic EGD who consent to undergo ePFT

Exclusion Criteria:

- If it is an emergency EGD procedure

- If the caregiver refuses to sign the consent form

- Patient has undergone ePFT testing previously with a documented allergy to human
secretin

- Patients that require atropine at the time of sedation